NexCure Launches with $19M to Bridge CAR-T Therapy Access Gap

BOSTON, MA – March 05, 2026 – A new healthcare startup, NexCure, Inc., launched today with $19 million in Series A financing and a bold mission: to dismantle the logistical and geographical walls that prevent most eligible patients from receiving advanced, life-saving treatments like CAR-T cell therapy. By creating a network of specialized outpatient clinics, the company aims to move these complex therapies out of a handful of elite academic hospitals and into communities, bringing care closer to home.

The financing round was led by RA Capital Management, with Cencora Ventures and Oncology Ventures participating, signaling strong investor confidence in a model that could fundamentally alter the delivery of cutting-edge medicine. The company was founded by Raven, RA Capital's healthcare incubator, specifically to address the stark reality of the current system.

"Today, only a fraction of patients who are eligible for CAR-T therapy actually receive it, largely due to where and how care is delivered," said Paul Rothman, MD, Founder and Board Chair of NexCure and a Venture Partner at Raven. "NexCure will work in partnership with the health ecosystem to thoughtfully expand access so more patients can receive advanced therapies in settings that are safe, effective and closer to home."

The Access Crisis in Advanced Cancer Care

CAR-T (Chimeric Antigen Receptor T-cell) therapy has been hailed as a revolutionary breakthrough, a living drug that re-engineers a patient's own immune cells to hunt and kill cancer. Yet, for all its promise, its reach is tragically limited. The press release highlights a critical bottleneck: of the 6,100 hospitals in the United States, only about 200—a mere 3%—are equipped and certified to administer the treatment.

This extreme concentration creates a landscape of deep inequity. Research shows that a patient's chance of receiving CAR-T therapy drops significantly with every mile they live from a certified treatment center. Some studies indicate that patients living just two to four hours away are nearly 40% less likely to receive the therapy. For those in rural or underserved areas, the treatment might as well be on another planet.

Beyond geography, the barriers are socioeconomic and logistical. The process requires patients and a caregiver to relocate near a treatment center for weeks of post-infusion monitoring, a demand that imposes crushing financial and personal burdens. This reality disproportionately impacts lower-income, elderly, and minority patients. Data reveals that Black patients and those in the lowest income brackets are significantly less likely to receive CAR-T than their White or wealthier counterparts. The result is a silent crisis where, according to some estimates, as few as two out of every ten eligible patients in the U.S. actually receive the treatment they need.

A New Model for Delivery: NexCure's Outpatient Vision

NexCure proposes to solve this crisis by de-centralizing care. The company's model is built on establishing purpose-built outpatient clinics that bring the clinical rigor of a hospital into a community setting. The core of this strategy is a proprietary technology platform designed to manage the immense complexity of CAR-T and other advanced therapeutics.

This platform aims to standardize clinical protocols, automate care coordination, and integrate remote patient monitoring. By doing so, NexCure believes it can reduce the operational variability that has kept these treatments tethered to large, resource-intensive academic centers. The goal is to ensure that a patient in a community clinic receives the same high standard of care and safety monitoring as one in a major urban hospital.

"I understand first hand the impact that cell therapy can deliver for people suffering from cancer and other diseases, and we are determined to surmount the operational barriers care providers face when attempting to provide access to these life-changing treatments," stated Sophie Papa, FRCP, PhD, Founder and Chief Medical Officer at NexCure. Dr. Papa, an internationally recognized expert in cellular therapy, emphasized the company's role in solving the challenge of delivering complex therapies with high monitoring needs directly to patients.

This model is designed to create a win-win for the entire healthcare ecosystem. Patients gain access without uprooting their lives. Referring community oncologists can offer their patients cutting-edge options. Overburdened academic centers can free up capacity for the most acute cases and research. And for pharmaceutical manufacturers, it creates a reliable, scalable network of sites to deliver their next-generation therapies.

The Business of Disruption: Investment and Infrastructure

The $19 million Series A financing is more than just startup capital; it's a validation of NexCure's disruptive potential. The involvement of venture firms like RA Capital, Cencora Ventures, and Oncology Ventures—each with deep expertise in life sciences and healthcare delivery—underscores the perceived market need.

"CAR-T and advanced oncology therapies are at a historic breakthrough moment, but the infrastructure to deliver them hasn't kept pace," said Ben Freeberg, Founder and Managing Partner of Oncology Ventures. "We are excited to invest in NexCure as they solve that bottleneck with a scalable outpatient clinic model that expands access, increases efficiency, and redefines where advanced therapeutics can be safely and efficiently delivered."

NexCure is helmed by a team with the credentials to execute this ambitious vision. Board Chair Paul Rothman is the former Dean of Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine. CEO Jennifer Smith brings over two decades of experience in scaling innovative clinical models. They are joined by Dr. Papa as CMO and Anish More as Chief Business Officer, who has extensive experience in operations and strategy for high-growth healthcare organizations.

Navigating Hurdles and Charting the Future

The path forward is not without significant challenges. Administering CAR-T therapy requires managing potentially severe side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity. The FDA mandates strict Risk Evaluation and Mitigation Strategies (REMS) for these therapies, and reimbursement models from payers like Medicare are largely built around the assumption of an inpatient hospital stay.

NexCure's success will depend on its ability to prove to regulators and payers that its technology-driven, protocol-standardized outpatient model is just as safe—if not safer—than the current standard. This will require rigorous data collection and a close partnership with regulatory bodies to potentially redefine certification and reimbursement for a new era of care delivery.

However, the company's vision extends beyond the current landscape of cancer treatment. As Dr. Rothman noted, the platform is being built with the future in mind. "As CAR-T matures and moves beyond oncology into autoimmune and other diseases, NexCure will work... to thoughtfully expand access," he stated. The infrastructure being built today could one day support a wide range of clinically intensive therapies, making the community clinic a hub for the most advanced medical innovations. By tackling the delivery problem head-on, NexCure is not just building a company; it is attempting to build the essential infrastructure for the future of medicine.